A Phase 2 interventional study of standard therapy and placebo in Acquired Bleeding Disorder and Bleeding During/Following Surgery, sponsored by Novo Nordisk A/S. Terminated at 7 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-02-27.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: standard therapy · Drug: placebo
Drug: standard therapy · Drug: activated recombinant human factor VII
Drug: standard therapy · Drug: activated recombinant human factor VII
Standard treatment of bleeding
Placebo
Two days repeated treatment regimen - low dose administered i.v. (into the vein)
Two days repeated treatment regimen - high dose administered i.v. (into the vein)
Effect on bleeding, defined as change in bleeding score
Transfusion requirements
Bleeding evaluation
Adverse events
Changes in safety coagulation parameters
Ran from Jun 2002 to primary completion in Oct 2003, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa